Figure 5
Figure 5. Regulated miRNAs in Tregs of SCT patients. Patients without GVHD and with GVHD manifestation before day 100 and after day 100 after SCT are summarized as “no GVHD” or “GVHD” > 100 days and > 100 days, respectively. CD4+CD25hiCD127lo/− Tregs were sorted from PBMCs of blood withdrawals with a purity > 95%. Isolated total RNA from n = 3 patients without GVHD and n = 3 patients with GVHD < 100 days and > 100 days were pooled, respectively. In addition, total RNAs were pooled from n = 3 healthy donors (HD). Results are presented as a heat map generated using Genesis software (Institute for Genomics and Bioinformatics, Graz University of Technology, Austria) and show 163 differentially regulated miRNAs with a log median fold change > 0.4 or < −0.5 in GVHD vs no GVHD < 100 days and/or GVHD vs no GVHD > 100 days. Red frames highlight miRNAs with predicted targets of gene transcripts encoding GZMA, LGALS1, CCR5, CD44, CXCR3, and CCR1.

Regulated miRNAs in Tregs of SCT patients. Patients without GVHD and with GVHD manifestation before day 100 and after day 100 after SCT are summarized as “no GVHD” or “GVHD” > 100 days and > 100 days, respectively. CD4+CD25hiCD127lo/− Tregs were sorted from PBMCs of blood withdrawals with a purity > 95%. Isolated total RNA from n = 3 patients without GVHD and n = 3 patients with GVHD < 100 days and > 100 days were pooled, respectively. In addition, total RNAs were pooled from n = 3 healthy donors (HD). Results are presented as a heat map generated using Genesis software (Institute for Genomics and Bioinformatics, Graz University of Technology, Austria) and show 163 differentially regulated miRNAs with a log median fold change > 0.4 or < −0.5 in GVHD vs no GVHD < 100 days and/or GVHD vs no GVHD > 100 days. Red frames highlight miRNAs with predicted targets of gene transcripts encoding GZMA, LGALS1, CCR5, CD44, CXCR3, and CCR1.

Close Modal

or Create an Account

Close Modal
Close Modal